HopeStage
Back to all studies
CompletedNCT01381419

Safety, Drug Levels and Brain Receptor Imaging of GSK1144814 in Healthy Adults

About this titleRead the official source — NCT01381419
Medication studyAges 18–55United KingdomSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 55 years.

Listed locations
HarrowSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 20, 2008
Recruitment status
Completed
Enrollment listed in the registry
21
Sponsor
GlaxoSmithKline
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 55 Years
Official registry ID
NCT01381419
Official title
Show the full official title

A Single-blind, Randomised, Placebo-controlled, Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1144814 in Healthy Male and Female Subjects and an Open-label Positron Emission Tomography Study in Healthy Male Subjects to Evaluate the Neurokinin-1 (NK1) Receptor Occupancy of GSK1144814 in the Living Human Brain Using 11C GR205171.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Harrow

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is GlaxoSmithKline.

Did this study involve medication?

Yes. The study involved medication, including GSK1144814.

Who was this study for?

Listed age limits: 18 years to 55 years.

Want to explore more studies?

Explore studies